Arrowhead Retires 15% Sixth Street Debt At A $68 Million Discount, Takes SOFR-Plus Loan

The RNAi drugmaker's new $400 million term loan matures in November 2031 and carries no required sweeps of partnership or product revenue.

Share
Arrowhead Retires 15% Sixth Street Debt At A $68 Million Discount, Takes SOFR-Plus Loan

Arrowhead Pharmaceuticals, which develops RNA interference medicines that silence disease-causing genes, repaid its $400 million Sixth Street facility at a $68 million discount to the contractual minimum repayment amount, the company said Wednesday. It replaced the loan with a new $400 million term loan from Sixth Street priced at 3-month SOFR plus 5.50%, against 15% a year on the old one.

Cheaper money, no sweeps

The retired facility carried a minimum 2x multiple on invested capital if repaid in full by August 2028, rising to 2.5x after that. The $68 million discount was negotiated off that contractual prepayment amount, the company said.

The old loan also required Arrowhead to repay part of it from a slice of certain proceeds, including upfront payments, milestones and royalties from partnerships and collaborations, plus its own commercial revenue. The new facility eliminates those required prepayments, the company said, and lowers the premiums for paying it off early.

The new loan matures on November 2, 2031. It has no scheduled amortization, so all principal comes due at maturity.

Prepayment terms and collateral

Arrowhead can prepay all or part of the loan at any time. A premium of no more than 2% applies to prepayments made more than 18 months after closing, plus a make-whole premium on any prepayment before May 2, 2028. Obligations are secured first-priority, subject to certain exceptions, by substantially all of the company's assets.

A commercial-stage balance sheet

Arrowhead's first commercial product, REDEMPLO (plozasiran), is FDA-approved as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome, a rare disease, according to its latest annual report. It also has license and collaboration agreements with partners including Sarepta Therapeutics, Amgen, Takeda, GSK and Novartis.

Chief Financial Officer Daniel Apel said the deal aligns the capital structure with "the company Arrowhead has become." He said that as Arrowhead builds the REDEMPLO business and advances its pipeline, the terms "more closely reflect our profile as a commercial-stage biopharmaceutical company."

Sixth Street's Jeff Pootoolal, a partner, and Michael Reslinski, a managing director, said the new structure recognizes the company's progress in turning its RNAi platform into a commercial business.

Under the new terms, milestone, royalty and product revenue stays with Arrowhead rather than being swept toward debt repayment.

Sources